By Joyce Lee
A new way of defining Alzheimer’s disease looks to frame it around the presence of “biomarkers,” or biological markers. Based on new guidelines from the National Institute on Aging and the Alzheimer’s Association, these biomarkers include amyloid protein buildup, tau protein buildup, and neurodegeneration in the brain.
“The new definition is an attempt to better explain why you might have cognitive problems, number one,” Penn Memory Center Co-Director Dr. Jason Karlawish told Healthline. “And number two, to give physicians the opportunity to prescribe treatments that might slow down or even prevent you from developing those cognitive problems.”